Evaluation of osteoporosis risk assessment in veterans receiving androgen-deprivation therapy

Consultant Pharmacist

Volumn 26, Issue 1, 2011, Pages 43-47

  D'Alesio, Valerie ^a,b   Salvig, Brent E ^a   Fourakre, T Neal ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Williamson Medical Center   (United States)

Author keywords

Androgen deprivation therapy; Bone mineral density; Dual energy x ray absorptiometry; Gonadotropin releasing hormone; Osteoporosis; Prostate cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; GOSERELIN; LEUPRORELIN; VITAMIN D; ANDROGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE MASS; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PATIENT ASSESSMENT; PROSTATE CANCER; VETERAN; BONE DENSITY; CHEMICALLY INDUCED; CROSS-SECTIONAL STUDY; DEFICIENCY; DRUG EFFECTS; METABOLISM; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

AGED; ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; CROSS-SECTIONAL STUDIES; GOSERELIN; HUMANS; LEUPROLIDE; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; VETERANS;

EID: 79953298278     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2011.43     Document Type: Article

References (21)

1. National Osteoporosis Foundation. Osteoporosis Fast Facts. 2008. Available at 〈http://www.nof.org/osteoporosis/diseasefacts.htm〉. Accessed August 13, 2009.
2. Bliuc D, Nguyen N, Milch VE et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009;301:513-21
3. Liu H, Paige NM, Goldzweig CL et al. Screening for osteoporosis in men: a systematic review for an American College of Physicians Guidelines. Ann Intern Med 2008;148:685-701.
4. National Cancer Institute. Prostate Cancer. 2008. Available at 〈http://www. cancer.gov/cancertopics/pdq/treatment/prostate/〉. Accessed August 2, 2009.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology-Prostate Cancer. 2009. Available at 〈http:// www.nccn.org/professionals/physician-gls/PDF/prostate.pdf〉. Accessed August 2, 2009.
6. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009; 115:2388-99.
7. Wilcox A, Carnes ML, Moon TD et al. Androgen deprivation in veterans with prostate cancer: implications for skeletal health. Ann Pharmacother 2006;40:2107-14. (Pubitemid 44954427)
8. Diamond TH, Higano CS, Smith MR et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy. Cancer 2004;100:892-9.
9. Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol 2007;177:17-24. (Pubitemid 44879461)
10. Baim S, Leonard MB, Bianchi ML et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom 2008;11:6-21.
11. The National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. 2008. Available at 〈http://www.nof.org/ professionals/NOF-Clinicians-Guide.htm〉. Accessed August 31, 2009.
12. Wadhwa VK, Weston R, Mistry R et al. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 2009;104:800-5.
13. Greenspan SL, Nelson JB, Trump DL et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer. Ann Intern Med 2007;146:416-24. (Pubitemid 351650576)
14. Panju AH, Breunis H, Cheung AM et al. Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. BJU Int 2008;103:753-7.
15. Tanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer 2005;103:237-41. (Pubitemid 40129281)
16. Shekelle P, Munjas, Liu H et al. Screening Men for Osteoporosis: Who & How. Department of Veterans Affairs. May 2007.
17. Adler RA, Tran MT, Petkov VI. Performance of the osteoporosis self-assessment screening tool for osteoporosis in American men. Mayo Clin Proc 2003;78:723-7. (Pubitemid 36665903)
18. Yee EFT, White RE, Murata GH et al. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med 2007;22:1305-10. (Pubitemid 47247311)
19. Bass E, Campbell RR, Werner DC et al. Inpatient mortality of hip fracture patients in Veterans Health Administration. Rehabil Nurs 2004;29:215-20.
20. American Cancer Society. Cancer Facts and Figures 2008. Available at 〈http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf〉. Accessed August 4, 2009.
21. Department of Veterans Affairs. Veteran Population Data. Available at 〈http://www1.va.gov/vetdata/〉. Accessed August 12, 2009.